Skip to main content
. Author manuscript; available in PMC: 2022 May 28.
Published in final edited form as: Cancer Lett. 2021 Mar 4;506:83–94. doi: 10.1016/j.canlet.2021.02.021

Fig. 6. CXCL7+ glioma-associated macrophages track with FGL2 expression and poor outcomes in human low-grade glioma.

Fig. 6.

(A), Heatmap of TCGA provisional low-grade glioma dataset clustered into GAMhi (n = 100), GAMmid (n = 181), and GAMlow (n = 235) groups on the basis of a gene signature for monocytic MDSCs/M2 macrophages. (B), Expression levels of FGL2 in 3 clustered groups of samples. FGL2 gene expression levels were compared among the TAM gene signature groups using t-tests, and P values were adjusted using the Bonferroni multiple testing correction. (C), Overall survival in the 3 clustered groups of patients. (D), Disease-free survival in the 3 clustered groups of patients. Kaplan-Meier survival analysis and the log-rank test were used to compare survival among the different TAM gene signature groups.